Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,987 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride (NaCl) Clear all
Completed Phase 4 Interventional

Tranexamic Acid for Total Knee Arthroscopy

NCT04443920
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Tranexamic acid (TXA), Placebo Normal Saline (NS)
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional Results available

Mechanisms of Insulin Facilitation of Memory

NCT01145482
View directory record Official record
Conditions
Memory Disorders
Interventions
Insulin, Saline
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

NCT01622348
View directory record Official record
Conditions
Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
13
States / cities
Jacksonville, Florida • Alpharetta, Georgia • Macon, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pertussis Vaccine in Healthy Pregnant Women

NCT00707148
View directory record Official record
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
4
States / cities
Durham, North Carolina • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00348608
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 25, 2026, 10:41 AM EDT
Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Mixed Exercise and Metabolic Stress in Relationship to Age in Healthy Men

NCT01800370
View directory record Official record
Conditions
Healthy
Interventions
Hyperglycemia, Saline, Exercise, Blood Draws, Fasting procedure
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain

NCT02184156
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
4 mL injection of Ampion, 4 mL injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Phase 2 Interventional

Plasma Injections Plus Exercise for Patellar Tendinopathy

NCT02116946
View directory record Official record
Conditions
Patellar Tendinopathy
Interventions
Platelet Rich Plasma (PRP), Saline + exercise
Biological · Other
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Vail, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting No phase listed Observational

Depression and Driving

NCT05446805
View directory record Official record
Conditions
Depression, Drive
Interventions
F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
150 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

NCT02108262
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
CSL112, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

NCT04767373
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Clesrovimab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 1 Year
Enrollment
3,632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
51
States / cities
Dothan, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Angiotensin II in Liver Transplantation

NCT04901169
View directory record Official record
Conditions
Liver Transplant; Complications, Vasoplegia
Interventions
Angiotensin II, Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa

NCT02805595
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
23.4% Hypertonic saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

NCT02487797
View directory record Official record
Conditions
Dystocia
Interventions
Oxytocin, Sodium Chloride 0.9%
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Phase 2 Interventional

Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department

NCT07868913
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan, Safety Planning
Drug · Other · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fort Hood, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Phase 2 Interventional

Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement

NCT07487246
View directory record Official record
Conditions
Pain Management, Abortion, Second Trimester Abortion, Dilation and Evacuation
Interventions
Ketorolac, oral ibuprofen, Placebo, Lidocaine HCl 1%, Saline
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Pilot Study of Bumetanide for Newborn Seizures

NCT00830531
View directory record Official record
Conditions
Seizures
Interventions
Bumetanide, Normal Saline as Placebo
Drug
Lead sponsor
Soul, Janet , M.D.
Individual
Eligibility
Up to 44 Weeks
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

NCT05413668
View directory record Official record
Conditions
Healthy
Interventions
RVP-001, Placebo
Drug
Lead sponsor
Reveal Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

NCT01843790
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
GCS-100, Placebo, Saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Phase 2 Interventional

Cleft Lip Scarring After Botox

NCT07880860
View directory record Official record
Conditions
Cleft Lip, Cleft Lip Scar
Interventions
Botulinum Toxin Type A (BOTOX) Injection, Normal Saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
0 Days to 12 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780424
View directory record Official record
Conditions
COVID-19
Interventions
BRII-196, BRII-198, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
76
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 25, 2026, 10:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study

NCT04547179
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab-Vfrm, BLAfit®, Saline
Drug · Device · Other
Lead sponsor
Manhattan Beach Orthodontics
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 25, 2026, 10:41 AM EDT
Not listed Phase 2 Interventional

Treatment of Hypopigmented Scars With Bimatoprost

NCT06122090
View directory record Official record
Conditions
Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
Interventions
Bimatoprost, Saline
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 25, 2026, 10:41 AM EDT